(Q38056892)

27 August 2017

title

Extended-release mesalamine granules for ulcerative colitis (English)

1 reference

27 August 2017

Bryan L Love

1

1 reference

27 August 2017

April D Miller

series ordinal

2

1 reference

27 August 2017

language of work or name

English

0 references

publication date

31 October 2012

1 reference

Annals of Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

46

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

1529-1536

1 reference

Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee

27 August 2017

cites work

1 reference

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

21 January 2018

1 reference

Multi-matrix system mesalamine: to use or not to use.

21 January 2018

1 reference

Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers

21 January 2018

1 reference

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

21 January 2018

1 reference

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

21 January 2018

1 reference

Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.

21 January 2018

1 reference

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial

21 January 2018

1 reference

Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial

21 January 2018

1 reference

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials

21 January 2018

1 reference

A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis

21 January 2018

1 reference

5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.

21 January 2018

1 reference

Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion

21 January 2018

1 reference

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines

21 January 2018

1 reference

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

5-ASA in ulcerative colitis: improving treatment compliance

21 January 2018

1 reference

Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations.

21 January 2018

1 reference

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies

21 January 2018

1 reference

Inaccuracies concerning Salofalk granules

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R171

1 reference

27 August 2017

1 reference